Annis Gardner Whiting Capital Advisors’s Charles River Laboratories CRL Stock Holding History

Annis Gardner Whiting Capital Advisors’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-86	Closed	-$14.8K	–	527
2026 Q1	$14.8K	Buy	86 +78	+975%	+$14.5K	﹤0.01%	802
2025 Q4	$1.6K	Buy	8 +5	+167%	+$907	﹤0.01%	990
2025 Q3	$470	Buy	+3	New	+$476	﹤0.01%	1088
2024 Q4	–	Sell	-56	Closed	-$11K	–	786
2024 Q3	$11K	Hold	56	–	–	﹤0.01%	535
2024 Q2	$11.6K	Buy	56 +18	+47%	+$4.08K	﹤0.01%	667
2024 Q1	$10.3K	Buy	38 +33	+660%	+$7.88K	﹤0.01%	666
2023 Q4	$1.18K	Hold	5	–	–	﹤0.01%	660
2023 Q3	$980	Buy	+5	New	+$1.03K	﹤0.01%	648

Other funds holding CRL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Annis Gardner Whiting Capital Advisors's CRL Position: Q2 2026 in Review

Annis Gardner Whiting Capital Advisors sold out of Charles River Laboratories (CRL) in Q2 2026, closing a stake of 86 shares — an estimated $14.8K sold.

Annis Gardner Whiting Capital Advisors first reported a position in CRL in Q3 2023 and held it in 8 quarters. The position peaked at $14.8K in Q1 2026. 563 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

Annis Gardner Whiting Capital Advisors reported no remaining Charles River Laboratories position as of Q2 2026 after selling out during the quarter.
Annis Gardner Whiting Capital Advisors sold 86 Charles River Laboratories shares in Q2 2026, an estimated $14.8K.
Annis Gardner Whiting Capital Advisors first reported a position in Charles River Laboratories in Q3 2023 and held it in 8 quarters.
Annis Gardner Whiting Capital Advisors's Charles River Laboratories position peaked at $14.8K in Q1 2026.
563 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Annis Gardner Whiting Capital Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.